ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2302

Clustering by ESSPRI and PROMIS domain measures defines distinct subtypes and facilitates longitudinal assessment of patients with Sjogren’s disease

Thomas Grader-Beck1, Jennifer Reed2, Priya Patel3, Ji Soo Kim4 and Alan Baer5, 1Johns Hopkins, Reisterstown, MD, 2Johns Hopkins, Freeland, MD, 3Johns Hopkins, Annville, PA, 4Johns Hopkins, Baltimore, MD, 5Johns Hopkins University School of Medicine, Baltimore, MD

Meeting: ACR Convergence 2025

Keywords: Cohort Study, Outcome measures, Sjögren's syndrome

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 28, 2025

Title: (2290–2304) Sjögren’s Disease – Basic & Clinical Science Poster III: Treatment and Trial Outcome Measures

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Patient-reported outcomes (PROs) measure a patient’s health-related quality of life. The role of ESSPRI and PROMIS measures in identifying subsets of patients with Sjogren’s disease is not established and longitudinal stability of these measures has not been assessed. This study uses PRO-based clustering to define distinct patient populations and measure cluster attribution in individual patients over time.

Methods: Data from 467 patients meeting ACR2016 criteria for Sjogren’s disease with at least 1 complete set of PRO data (ESSPRI Dryness/Fatigue and Pain and PROMIS Physical function/Ability to participate/Sleep Interference/Anxiety and Depression) were extracted from the Epic Electronic Health Record system. Baseline Clustering was completed using k-means clustering algorithm. For longitudinal analysis, an alluvial plot of 198 patients with at least two visits with complete PRO data was created to visualize transitions of patients between clusters. Statistical analysis between clusters was done using ANOVA, Chi-squared, and Fisher’s exact tests.

Results: K-means algorithm identified 4 clusters of patients at baseline: cluster 1 (77/467; 16.5%), Low symptoms/high function (LSHF), cluster 2 (130/467; 27.8%), High symptoms/balanced function (HSBF), cluster 3 (116/467; 24.8%), Moderate symptoms/balanced function (MSBF), and cluster 4 (144/467; 30.8%), High symptoms/poor function (HSPF) (Figure 1). Demographic variables, including age, sex, and race, anti-SSA/Ro positivity, disease phenotypic markers and DMARD exposure did not differ between clusters (Table 1). Abnormal salivary flow was least frequent in the LSHF cluster (29/77; p=0.008 by Chi-squared test). Abnormal Schirmer’s and hypergammaglobulinemia were least frequent in the HSPF cluster (95/144;70.4% p=0.012 and 40/144; 28.6% p=0.025 by Chi-squared test, respectively). Longitudinal analysis of cluster stability in 198 patients over 2 to 4 visits demonstrated that most patients (54.0%) remained in the same cluster over time (Figure 2). Transitions between extreme clusters (LSHF and HSBF) were significantly less frequent than other transitions (3/35 vs 93/96; p< 1X1022, Fisher’s exact test).

Conclusion: ESSPRI and PROMIS measures define distinct clusters in patients with Sjogren’s disease. Cluster attribution of individual patients remains relatively stable over time and changes between extreme clusters is rare. Prospective studies are needed to further define the relationship between cluster stability, disease flares and response to therapy.

Supporting image 1Table 1: Baseline characteristics in clusters of patients with Sjogren’s disease. 1 Adjusted n to account for missing data. 2 Ever present. Abbreviations: LSHF (low symptoms/high function), HSBF (high symptoms/balanced function), MSBF (moderate symptoms, balanced function), HSPF (high symptoms/poor function

Supporting image 2Figure 1:Heatmap of clusters 1-4. Average values of each PRO measure are shown. PROMIS Ability to Participate and Physical Function values are subtracted from 100 to reflect reverse significance.

Supporting image 3Figure 2: Alluvial plot demonstrating cluster attribution of individual patients over time.


Disclosures: T. Grader-Beck: Argenx, 5, 12, Consulting fees, Bristol-Myers Squibb(BMS), 5, 12, Consulting fees, Novartis, 5, 12, Consulting fees; J. Reed: None; P. Patel: None; J. Kim: None; A. Baer: Bristol-Myers Squibb(BMS), 2.

To cite this abstract in AMA style:

Grader-Beck T, Reed J, Patel P, Kim J, Baer A. Clustering by ESSPRI and PROMIS domain measures defines distinct subtypes and facilitates longitudinal assessment of patients with Sjogren’s disease [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/clustering-by-esspri-and-promis-domain-measures-defines-distinct-subtypes-and-facilitates-longitudinal-assessment-of-patients-with-sjogrens-disease/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/clustering-by-esspri-and-promis-domain-measures-defines-distinct-subtypes-and-facilitates-longitudinal-assessment-of-patients-with-sjogrens-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology